The article is interesting in that it links this study, which concerns the use of BTM as a site for nourishing and housing therapeutic cells, to the use of BTM as site for drug elution. The implied suggestion here is that BTM’s potential for drug elution may have been brought to the attention of Novo Nordisk through this study.
That this can even be speculated on demonstrates the extraordinary range of use for the platform tech NovoSorb. It’s a reminder, that even though a great deal of money is yet to be made in expanding the sales, markets and products for dermal regeneration, there is enormous potential for other silos of activity outside of wound care.
PNV Price at posting:
$1.51 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)